Core B is a Neuropathology and Biomarker Core (NP Core) that plays a vital role in the UCSF FTD PPG. FTLD neuropathology has become increasingly exciting and complex in recent years, with major advances arising from w/ork accomplished through this PPG. During the past two cycles. Core B has been led by Dr. John Trojanowski at the University of Pennsylvania (PENN). In this renewal application, we propose to centralize Core B functions at UCSF through an NP Core led by Dr. William Seeley and to add a new cerebrospinal fluid (CSF) biomarker component led by Drs. Trojanowski and Leslie Shaw at PENN. The new NP Core aims to: (1) Obtain CNS tissue for NP characterization and banking by performing timely autopsies on patients and healthy controls ascertained through Core A;(2) Analyze specimens and document NP diagnoses by dissecting a standard set of 23 regions-of-interest for routine histological staining and systematic immunohistochemical characterization;(3) Enter NP findings into a comprehensive research oriented database;(4) Bank and distribute CNS tissues by reviewing tissue requests by committee and providing samples to qualified investigators for research;and (5) Store and analyze CSF for diagnostic biomarkers by receiving CSF samples from an average of 45 patients per year with FTD or AD clinical diagnoses and performing CSF total tau, phospho-tau and beta-amyloid levels on every sample. These core functions will support the aims of Projects 2 (Multi-modal imaging), 3 (Emotions), and 4 (Clinical criteria) by providing final neuropathological diagnoses that serve as primary outcomes or grouping variables. Moreover, the NP Core will help to futher develop a unique bank of specially handled CNS tissues (brain, spinal cord, and CSF) for ongoing and future FTLD molecular, translational, clinicopathological, and biomarker discovery research.
| Erkkinen, Michael G; Zúñiga, Raquel Gutiérrez; Pardo, Cristóbal Carnero et al. (2018) Artistic Renaissance in Frontotemporal Dementia. JAMA 319:1304-1306 |
| Schneider, Raphael; McKeever, Paul; Kim, TaeHyung et al. (2018) Downregulation of exosomal miR-204-5p and miR-632 as a biomarker for FTD: a GENFI study. J Neurol Neurosurg Psychiatry 89:851-858 |
| Ljubenkov, Peter A; Staffaroni, Adam M; Rojas, Julio C et al. (2018) Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory. Ann Clin Transl Neurol 5:1250-1263 |
| La Joie, Renaud; Bejanin, Alexandre; Fagan, Anne M et al. (2018) Associations between [18F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. Neurology 90:e282-e290 |
| Kim, Eun-Joo; Brown, Jesse A; Deng, Jersey et al. (2018) Mixed TDP-43 proteinopathy and tauopathy in frontotemporal lobar degeneration: nine case series. J Neurol 265:2960-2971 |
| Henry, Maya L; Hubbard, H Isabel; Grasso, Stephanie M et al. (2018) Retraining speech production and fluency in non-fluent/agrammatic primary progressive aphasia. Brain 141:1799-1814 |
| Nana, Alissa L; Sidhu, Manu; Gaus, Stephanie E et al. (2018) Neurons selectively targeted in frontotemporal dementia reveal early stage TDP-43 pathobiology. Acta Neuropathol : |
| Vatsavayai, Sarat C; Nana, Alissa L; Yokoyama, Jennifer S et al. (2018) C9orf72-FTD/ALS pathogenesis: evidence from human neuropathological studies. Acta Neuropathol : |
| Ossenkoppele, Rik; Rabinovici, Gil D; Smith, Ruben et al. (2018) Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA 320:1151-1162 |
| Mandelli, Maria Luisa; Welch, Ariane E; Vilaplana, Eduard et al. (2018) Altered topology of the functional speech production network in non-fluent/agrammatic variant of PPA. Cortex 108:252-264 |
Showing the most recent 10 out of 607 publications
